SURE CANADA: A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once Weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SURE CANADA
- Sponsors Novo Nordisk
- 22 Jul 2019 Planned number of patients changed from 217 to 460.
- 22 Jul 2019 Planned End Date changed from 25 Nov 2019 to 25 Dec 2019.
- 22 Jul 2019 Status changed from recruiting to active, no longer recruiting.